4E-BP1 is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways That Integrates Their Function in Tumors

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2010 Jul 9

PMID 20609351

Citations 228

Authors

Qing-Bai She

Ensar Halilovic

Qing Ye

Wei Zhen

Senji Shirasawa

Takehiko Sasazuki

David B Solit

Neal Rosen

Affiliations

Soon will be listed here.

Abstract

PIK3CA and PTEN alterations are common in human cancer, but only a fraction of such tumors are dependent upon AKT signaling. AKT independence is associated with redundant activation of cap-dependent translation mediated by convergent regulation of the translational repressor 4E-BP1 by the AKT and ERK pathways. This provides mechanistic bases for the limited activity of AKT and MEK inhibitors in tumors with comutation of both pathways and the profound synergy observed with combined inhibition. Whereas such tumors are sensitive to a dominant active 4E-BP1 mutant, knockdown of 4E-BP1 expression reduces their dependence on AKT/ERK signaling for translation or survival. Thus, 4E-BP1 plays a prominent role in mediating the effects of these pathways in tumors in which they are activated by mutation.

Citing Articles

Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer.

Mahmoud A, Choi P, Sukhwa C, Pintar J, Walch H, Zhao N bioRxiv. 2025; .

PMID: 40027618 PMC: 11870485. DOI: 10.1101/2025.02.17.638725.

Noncanonical feedback loop between "RIP3-MLKL" and "4EBP1-eIF4E" promotes neuronal necroptosis.

Wang S, Zhang Y, Wang M, Zhai Z, Tan Y, Xu W MedComm (2020). 2025; 6(3):e70107.

PMID: 39974664 PMC: 11836343. DOI: 10.1002/mco2.70107.

Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells.

Lum M, Jonas K, Parmar S, Black A, OConnor C, Dobersch S J Clin Invest. 2025; 135(4).

PMID: 39869680 PMC: 11827888. DOI: 10.1172/JCI176093.

Global transcriptomic network analysis of the crosstalk between microbiota and cancer-related cells in the oral-gut-lung axis.

Otalora-Otalora B, Payan-Gomez C, Lopez-Rivera J, Pedroza-Aconcha N, Aristizabal-Guzman C, Isaza-Ruget M Front Cell Infect Microbiol. 2024; 14:1425388.

PMID: 39228892 PMC: 11368877. DOI: 10.3389/fcimb.2024.1425388.

Combined inhibition of KRAS and mTORC1 kinase is synergistic in non-small cell lung cancer.

Kitai H, Choi P, Yang Y, Boyer J, Whaley A, Pancholi P Nat Commun. 2024; 15(1):6076.

PMID: 39025835 PMC: 11258147. DOI: 10.1038/s41467-024-50063-z.

References

Bilodeau M, Balitza A, Hoffman J, Manley P, Barnett S, Defeo-Jones D . Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett. 2008; 18(11):3178-82. DOI: 10.1016/j.bmcl.2008.04.074. View

Tsao H, Goel V, Wu H, Yang G, Haluska F . Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004; 122(2):337-41. PMC: 2586668. DOI: 10.1046/j.0022-202X.2004.22243.x. View

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

Feldman M, Apsel B, Uotila A, Loewith R, Knight Z, Ruggero D . Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7(2):e38. PMC: 2637922. DOI: 10.1371/journal.pbio.1000038. View

Wee S, Jagani Z, Xiang K, Loo A, Dorsch M, Yao Y . PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009; 69(10):4286-93. DOI: 10.1158/0008-5472.CAN-08-4765. View

Pause A, Belsham G, Gingras A, Donze O, Lin T, Lawrence Jr J . Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature. 1994; 371(6500):762-7. DOI: 10.1038/371762a0. View

Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B . 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res. 2007; 67(16):7551-5. DOI: 10.1158/0008-5472.CAN-07-0881. View

Manning B, Tee A, Logsdon M, Blenis J, Cantley L . Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002; 10(1):151-62. DOI: 10.1016/s1097-2765(02)00568-3. View

Thoreen C, Kang S, Chang J, Liu Q, Zhang J, Gao Y . An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284(12):8023-32. PMC: 2658096. DOI: 10.1074/jbc.M900301200. View

10.

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

11.

Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R . An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther. 2010; 9(7):493-503. PMC: 2987445. DOI: 10.4161/cbt.9.7.11100. View

12.

Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras A, Crosby K . Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA. 2008; 14(7):1318-27. PMC: 2441981. DOI: 10.1261/rna.950608. View

13.

Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler L, Sonenberg N . eIF4E--from translation to transformation. Oncogene. 2004; 23(18):3172-9. DOI: 10.1038/sj.onc.1207549. View

14.

Jacobson B, Alter M, Kratzke M, Frizelle S, Zhang Y, Peterson M . Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res. 2006; 66(8):4256-62. DOI: 10.1158/0008-5472.CAN-05-2879. View

15.

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

16.

Wendel H, de Stanchina E, Fridman J, Malina A, Ray S, Kogan S . Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428(6980):332-7. DOI: 10.1038/nature02369. View

17.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

18.

Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A . Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118(9):3065-74. PMC: 2518073. DOI: 10.1172/JCI34739. View

19.

Graff J, Konicek B, Carter J, Marcusson E . Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 2008; 68(3):631-4. DOI: 10.1158/0008-5472.CAN-07-5635. View

20.

Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner G, Zepf D . PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008; 10(6):534-41. PMC: 2386538. DOI: 10.1593/neo.08336. View